![](https://library.celltelligence.com/wp-content/uploads/2023/06/Screenshot-2023-06-01-at-15.34.30.png)
$0
Azer-cel’s Potential Ph2 Trial in CAR-T-Relapsed DLBCL Patients; Clinical Updates for Azer-cel and PBCAR19B; Precision’s Mid-Year 2023 Event
On Wednesday, May 31, Precision Biosciences held its mid-year 2023 pipeline update event (press release / presentation), highlighting plans to hold a meeting with the FDA to discuss a potential Ph2 trial evaluating azer-cel (allogeneic CD19 CAR-T) in DLBCL patients who relapsed after autologous CAR-T therapy. Additionally, management presented clinical updates for both allogeneic CD19 CAR-Ts (azer-cel and PBCAR19B). Below, Celltelligence provides insights on azer-cel’s improved safety profile due to the company’s manufacturing optimization process while discussing its potential to be a first-in-class allogeneic CAR-T for CD19+ CAR-T-relapsed patients.